goetzpartners advised the shareholders on the sale of Vibalogics to Ampersand Capital Partners

goetzpartners was mandated as exclusive M&A advisor on the sale of VIBALOGICS, a rapidly growing CDMO offering GMP-compliant manufacturing and development services for the international biopharmaceutical industry, to the US-based private equity firm Ampersand Capital Partners.

VIBALOGICS offers process development, manufacturing and fill & finish of products for biopharmaceutical companies involved in the development of oncolytic viral therapies, gene therapies, and vaccines. With a specific focus on viruses, live bacteria, and aseptic processing, the Company’s 50 employees work in full compliance with international GMP standards in a BSL-2 classified state-of-the-art, 27,000 sq. ft. facility in Cuxhaven, Germany.

Stefan Beyer, Ph.D., CEO of VIBALOGICS commented, “With the benefit of Ampersand as our partner, VIBALOGICS will now strengthen and expand its position in the US and European markets while further investing in additional process development and GMP manufacturing capabilities. The partnership solidifies VIBALOGICS' existing presence in the biologics manufacturing space and will allow the company to continue to exceed our customers’ expectations by facilitating the development of innovative therapeutic approaches that significantly improve the treatment of patients suffering from cancer and genetic disorders. We are very pleased to have Ampersand on board as we take VIBALOGICS through to its next phase of growth.”

David Anderson, General Partner at Ampersand said, “VIBALOGICS is a leading company in its field and given the exciting developments within the complex virus market this is an excellent time for an investor with deep experience in the viral vector contract manufacturing sector to partner with the company. We are looking forward to working with the team at VIBALOGICS to accelerate and continue its success in delivering cutting-edge therapies to patients in need.”

goetzpartners Corporate Finance acted as exclusive M&A advisor to the shareholders, further underlining our competence as advisor of choice in the healthcare industry and in cross-border M&A transactions. The Purchase Agreement is subject to customary closing conditions.

ABOUT VIBALOGICS GMBH

VIBALOGICS is a contract development and manufacturing organization (CDMO) with facilities in Cuxhaven, Germany, providing process development and GMP manufacturing services. Founded in 2002, the company is recognized as a leading service provider within the live biologics development and manufacturing industry.

ABOUT AMPERSAND CAPITAL PARTNERS

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. Ampersand has helped build numerous market-leading companies across each of its core healthcare sectors, including Avista Pharma Solutions, Brammer Bio, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories.

TRANSACTION TEAM

Ulrich Kinzel
Managing Director
Email

Wolf Dornbusch
Director

Daniel Mövius
Associate Director

Fabio Riva
Analyst